Enzolytics Inc - ENZC STOCK NEWS

Welcome to our dedicated news page for Enzolytics (Ticker: ENZC), a resource for investors and traders seeking the latest updates and insights on Enzolytics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enzolytics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enzolytics's position in the market.

04/23/2024 08:30 AM

News

Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada

Rhea-AI Summary

Enzolytics Inc. announced the dismissal of the Dimitar Savov lawsuit in Nevada, marking the end of a two-year legal battle. The company updated on the OTC annual report progress and business model shift towards sales, marketing, and distribution services for medical devices, nutraceutical, and medical testing technology. Enzolytics is actively defending against litigation and expects to resolve administrative issues soon.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/12/2024 09:27 AM

News

Update on Formulation of New Business Strategy

Rhea-AI Summary

Enzolytics, Inc. announces new board of directors and executive officers, along with an update on the formulation of a new business strategy. The company is targeting acquisitions, license agreements, and dividend distribution of SAGA shares.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-8.14%

Tags

03/25/2024 10:00 AM

News

ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD

Rhea-AI Summary

Enzolytics, Inc. appoints new board of directors and executive officers. The company aims to develop a new business strategy and pursue acquisition targets.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-17.05%

Tags

01/16/2024 08:00 AM

News

Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity

Rhea-AI Summary

Enzolytics, Inc. partners with The Khalpey AI Lab to use artificial intelligence in drug development to improve organ recovery and longevity. The collaboration aims to revolutionize medical science, introduce new testing services, and advance research on neurodegenerative diseases. The partnership is expected to lead to groundbreaking discoveries in aging research and the development of therapeutic solutions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.42%

Tags

11/20/2023 09:10 AM

News

Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

Rhea-AI Summary

Enzolytics, Inc. (ENZC) provides updates on the SAGA transaction, Virogenetics, Inc., and Biogenysis, Inc. progress. The company filed amended OTC Annual Report and quarterly disclosure, completed the sale of VIRO and BGEN to SAGA, and received 45 million SAGA shares. The African clinical trial for ITV-1 is being conducted in Ethiopia, with additional trials in Asia and India. VIRO's nutraceutical product line expansion and Biogenysis, Inc.'s progress in its PCT application for anti-SARS-CoV-2 Monoclonal Antibodies are also highlighted.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-14.22%

Tags

09/18/2023 08:00 AM

News

Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)

Rhea-AI Summary

Enzolytics, Inc. announces the sale of Biogenysis, Inc. and Virogentics Inc. to Sagaliam Acquisition Corp in a $450 million transaction, expected to trade on NASDAQ. The sale provides funding for the development of therapeutics for treating viruses.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

29.72%

Tags

09/06/2023 08:45 AM

News

Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")

Rhea-AI Summary

VIRO announces start date for ITV-1 clinical trials in late 2023 or early 2024. R&D Services will manage the trials in Bulgaria. VIRO's nutraceutical division shows growth in the North American market. Potential revenue of over $2 billion from autoimmune and diabetes markets. VIRO files utility patent applications. ENZC provides SAGA with draft of Business Combination Agreement. Enzolytics advancing multiple therapeutics targeting infectious diseases. ITV-1 has shown effectiveness in treating HIV/AIDS. VIRO has proprietary technology for producing monoclonal antibodies against infectious diseases.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.79%

Tags

09/05/2023 08:00 AM

News

Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.

Rhea-AI Summary

Enzolytics' subsidiary Biogenysis partners with Khalpey AI Lab and Contenta, Ltd. to identify biomarkers for early onset Alzheimer's disease, potentially leading to early diagnosis and preventative therapies. Alzheimer's disease affects over 6 million people in the US and is expected to double by 2050, resulting in an annual cost of nearly $1 trillion. Developing accurate diagnostic tests and biomarkers is crucial. The partnership aims to analyze the gut microbiota of thousands of patients to identify those at higher risk of developing dementia and design preventative treatments. This collaboration is a significant step forward in the fight against Alzheimer's disease.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.38%

Tags

08/24/2023 08:00 AM

News

Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.

Rhea-AI Summary

Biogenysis, a subsidiary of Enzolytics, has advanced its Patent Cooperation Treaty (PCT) application for Anti-SARS-CoV-2 Monoclonal Antibodies to the U.S. National Stage Application and the European Patent Organization. The pending applications cover 23 patent claims related to the antigens, antibodies, vaccines, and methods for treating and diagnosing SARS-CoV-2 infection. The Company's unique AI technology has identified conserved virus sites on the COVID-19 virus, allowing for the production of specialized monoclonal antibodies that can neutralize the virus even as it mutates. The expected patent protection is highly significant for the Company. The global market size for effective treatments in 2022 was $16.43 billion, and the global Monoclonal Antibodies market size was $185.50 billion in 2021 with an expected CAGR of 11.30% from 2022 to 2030.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

Tags

08/08/2023 01:00 PM

News

Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment

Rhea-AI Summary

Enzolytics, Inc. subsidiary Virogentics has received an export permit for the delivery of treatments to HIV/AIDS patients in Africa. The results of this pilot clinical trial will be used for European Medicine Authority clinical trials. Sagaliam Acquisition Corp. has extended the time to consummate a business combination agreement with VIRO. The CEO of Sagaliam praises VIRO's progress and their potential to help people globally. VIRO is moving closer to administering their immunotherapy and listing on NASDAQ.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags